Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response
Authors:
- Edward L.C PritchettEdward L.C Pritchett
- Richard L PageRPRichard L Page
- Stuart J ConnollySCStuart J Connolly
- Stephen R MarcelloSMStephen R Marcello
- Daniel J SchnellDSDaniel J Schnell
- William E WilkinsonWWWilliam E Wilkinson
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Incidence of and Risk Factors for Atrial Fibrillation in Older AdultsCirculation, 1997
- Classification of Atrial FibrillationPacing and Clinical Electrophysiology, 1997
- Pharmacology of Azimilide Dihydrochloride (NE‐10064), A Class III Antiarrhythmic AgentCardiovascular Drug Reviews, 1997
- Paroxysmal A trial Fibrillation:Journal of Cardiovascular Electrophysiology, 1995
- Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia.Circulation, 1994
- Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.Circulation, 1990
- Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.Circulation, 1989
- Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatmentThe American Journal of Cardiology, 1988
- Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillationEuropean Heart Journal, 1981